WFDC2 and endometrial cancer: The strongly positive expression rate of HE4 in endometrial cancer was 31.57% at stage Ia, 56.52% at stage Ib, 28.57% at stage II, 71.42% at stage III, and 83.33% at stage IV, respectively, which showed an increasing tendency with increased clinical stage (PIa:III = 0.001, PIa:IV = 0.016, PI:III = 0.008, PI:IV = 0.047, PII:III = 0.035, PII:IV = 0.048, and P(I+II):(III+IV) = 0.001).